Q2 2025 Management View Punit S. Dhillon, President and CEO, highlighted the imminent reporting of Phase IIa data for ...

Detailed price information for Skye Bioscience Inc (SKYE-Q) from The Globe and Mail including charting and trades.

Skye Bioscience Inc (SKYE) reports significant advancements in clinical trials and financial stability, despite increased ...

Detailed price information for Skye Bioscience Inc (SKYE-Q) from The Globe and Mail including charting and trades.

Skye Bioscience, Inc., a biotechnology company specializing in treatments for obesity and metabolic disorders, announced the launch of its "Anatomy of Progress" video series, showcasing the ...

Skye Bioscience’s nimacimab blocks CB1, the same receptor targeted by an obesity drug candidate now in the hands of Novo Nordisk. But Skye contends its Phase 2-ready antibody drug has several ...

SAN DIEGO, March 20, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical stage biopharmaceutical company pioneering next-generation ...

Skye preparing to start Phase 2a glaucoma clinical trial in Q3San Diego, California-- (Newsfile Corp. - July 13, 2023) - Skye Bioscience, Inc. (OTC ...

About Skye Bioscience Skye is focused on unlocking the pharmaceutical potential of the endocannabinoid system to treat diseases with metabolic, inflammatory, and fibrotic processes.

Skye Bioscience, Inc. announced that it has granted stock options for 56,000 shares of its common stock to two new non-executive employees as part of its 2024 Inducement Equity Incentive Plan, in ...

Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on advancing new therapeutic ...

Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Mar. 20, 2025 4:01 PM ET Skye Bioscience, Inc. (SKYE) ...